ArticleHarm reduction journal2025
Anabolic-androgenic steroid testing as a tool for consumer engagement and harm reduction: a sequential explanatory mixed-method study.
Article in Harm reduction journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Making 'safer injecting' matter for people who inject image and performance enhancing drugs.Health (London, England : 1997) · 2026Article
- Co-producing a peer-led health conversation tool for the health services workforce to facilitate safer use of anabolic-androgenic steroids.Harm reduction journal · 2025Article
- Associations in intentions to use anabolic-androgenic steroids among non-consuming boys and men with probable eating disorders and muscle dysmorphia.Journal of eating disorders · 2025Article
- Looking for the Best Way to Come Off Steroids Safely? Exploring Post-Cycle Therapy, Cessation, and Recovery Discourse and Practice in Australian Steroid Consumer Forums.Drug and alcohol review · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnabolic-androgenic steroid (AAS) use is widespread, yet regulation remains limited, exposing consumers to misidentified and contaminated products. This study expands AAS testing by enhancing purity analysis, identifying branding inconsistencies, and examining consumer responses. It aims to evaluate the impact of enhanced testing and feedback on consumer behaviour and harm reduction.
methodsThis is a sequential explanatory mixed-methods study incorporating chemical analysis of community-submitted AAS samples and interviews with participants. Interviews used semi-structured formats, focusing on participants' understanding of the testing results, and how it influenced their AAS usage decisions. We sampled from community harm reduction organisations across two drug checking sites in Queensland, Australia.
resultsBetween April 19 and August 16, 2024, 58 AAS samples were submitted. Chemical analysis was conducted using Radian-ASAP direct mass spectrometry and Orbitrap Liquid Chromatography Mass Spectrometry to verify the identity and dosage of the submitted AAS. Of the 46 analysable samples, 9 exhibited presence issues (i.e., the compound differed from expectations), while 15 demonstrated purity issues (i.e., the concentration was either too low or too high). Twenty-five AAS consumers were interviewed, with follow-up interviews conducted with 15 participants to assess their behaviour changes. Interviews (N = 40) indicated that consumers' trust in the substances they used was reduced, leading to more cautious approaches and reconsideration of usage practices.
conclusionThis study demonstrates that chemical analysis can be a powerful tool in influencing AAS consumers' practices, highlighting the need for further research on how testing, coupled with harm reduction interventions, can improve consumer safety and decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.